{
    "clinical_study": {
        "@rank": "63575", 
        "arm_group": [
            {
                "arm_group_label": "Bosentan group", 
                "arm_group_type": "Experimental", 
                "description": "Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR."
            }, 
            {
                "arm_group_label": "Routinely group", 
                "arm_group_type": "No Intervention", 
                "description": "Routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR."
            }
        ], 
        "brief_summary": {
            "textblock": "Bosentan is a kind of dual endothelin receptor antagonist.The purpose of this study is to\n      investigate if Bosentan therapy can modify the outcome of children with functional single\n      ventricle."
        }, 
        "brief_title": "Bosentan Therapy in Children With Functional Single Ventricle", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Congenital Heart Defects", 
            "Functional Single Ventricle"
        ], 
        "condition_browse": {
            "mesh_term": "Heart Defects, Congenital"
        }, 
        "detailed_description": {
            "textblock": "Increased pulmonary vascular resistance (PVR) is a serous issues in children with functional\n      single ventricle during the staged operative period. The purpose of this study is to\n      investigate if Bosentan therapy can improve the survival and life quality after staged\n      Fontan procedure in the children with high risk of increased PVR."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent obtained from patient's legally acceptable representative.\n\n          -  Pediatric patients waiting for staged Fontan procedure with high risk of increased\n             PVR after bidirectional cavopulmonary connection (BCPC)\n\n               -  Transpulmonary pressure gradiant (TPG) > 10mmHg when the obstruction of\n                  anastomosis and lung problem were excluded.\n\n               -  With the diagnosis of high risk of increased PVR, such as associated with TAPVC,\n                  after pulmonary artery banding, after systemic to pulmonary shunt more than 6\n                  months, and et al.\n\n               -  Diagnosed as increased PVR with catheterization.\n\n        Exclusion Criteria:\n\n          -  PAH associated with conditions other than those mentioned above, e.g., iPAH, PAH\n             secondary to portal hypertension, HIV patient with opportunistic infection\n\n          -  Psychotic, addictive or other disorder limiting the ability to provide informed\n             consent or to comply with study requirements\n\n          -  AST and/or ALT > 3 times the upper limit of normal ranges.\n\n          -  Hemoglobin concentration < 75% the lower limit of normal ranges\n\n          -  Treatment or planned treatment with another investigational drug within 3 months of\n             screening\n\n          -  Treatment with calcineurin-inhibitors (e.g., cyclosporine A and tacrolimus),\n             fluconazole, glibenclamide (glyburide) within 1 week of enrollment of this study\n\n          -  Known hypersensitivity to bosentan or any of the excipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "4 Months"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662037", 
            "org_study_id": "SJTUMS-20120314"
        }, 
        "intervention": {
            "arm_group_label": "Bosentan group", 
            "description": "Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.", 
            "intervention_name": "Bosentan", 
            "intervention_type": "Drug", 
            "other_name": "Tracleer"
        }, 
        "intervention_browse": {
            "mesh_term": "Bosentan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary vascular resistance", 
            "Heart defects, Congenital", 
            "Receptors, endothelin", 
            "Bosentan"
        ], 
        "lastchanged_date": "August 7, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200127"
                }, 
                "name": "Cardiac intensive care unit, Department of cardiothoracic vascular surgery, Shanghai Children's Medical Center, Medical college of Shanghai Jiaotong University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bosentan Therapy for High Risk Staged Fontan Procedure in Children With Functional Single Ventricle", 
        "overall_official": {
            "affiliation": "Cardiac intensive care unit, Department of Thoracic and cardiovascular Surgery, Shanghai children's Medical Center", 
            "last_name": "Zhuoming Xu, MD PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Length of hospital stay and ICU stay", 
            "safety_issue": "No", 
            "time_frame": "12 months after Fontan operation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662037"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Limin Zhu", 
            "investigator_title": "Attendant doctor, Department of thoracic and cardiovascular surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "facial edema plural effusion pericardium effusion", 
                "measure": "Symptoms of increased PVR", 
                "safety_issue": "No", 
                "time_frame": "12 months after Fontan operation"
            }, 
            {
                "measure": "WHO functional class", 
                "safety_issue": "No", 
                "time_frame": "12 months after Fontan operation"
            }
        ], 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}